If you're obese but don't have diabetes, taking GLP-1 drugs like Ozempic for five years doesn't seem to raise your risk of joint problems like arthritis or needing joint surgery — so if joint issues show up in people with diabetes on these drugs, it might be because of their diabetes, not the drug itself.
See the scientific wording
In obese adults without diabetes, long-term (five-year) use of GLP-1 receptor agonists is not associated with an increased risk of hip or knee osteoarthritis, total joint arthroplasty, or other joint-related adverse outcomes, indicating that joint-related risks observed in diabetic populations may be attributable to underlying metabolic or disease-specific factors rather than the pharmacological effects of GLP-1 receptor agonists alone.
Contradicted by evidence
ObservationalOne moderate-quality study contradicts this claim, though the evidence is not conclusive.
What the research says
1 study reviewedSupporting (0)
No supporting studies found yet
We'll keep looking as more research is published.
Contradicting (1)
Cohort StudyHuman2024
The study found that obese adults without diabetes who took GLP-1 drugs for five years did not have higher rates of joint problems compared to those who didn’t, which supports the idea that the drug itself isn’t causing joint issues in this group.
Quality-weighted scoring: we follow the GRADE framework — each study is rated High, Moderate, Low, or Very Low based on study design, methodology rigor, and risk of bias. A single high-quality RCT can outweigh several weaker observational studies.
Scores reflect study quality, not just count.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 contradicting study
How Fit Body Science checks a claim
- 1
We isolate the claim
Health advice from videos, articles and studies is broken down into single, testable claims.
- 2
We find the research
Each claim is matched against peer-reviewed studies, with every source cited by DOI.
- 3
We grade the evidence
Studies are scored on methodology, statistical rigor, transparency and publication quality.
The fitness and health internet is full of confident claims. We check them against real research.
Every claim on this site is traced back to peer-reviewed studies, scored on methodology and reporting quality, and given a verdict you can audit yourself — sources, DOIs and all.
- Full evidence breakdown and mechanism chains
- Ask our AI anything about a claim or its studies
- Get notified when new research changes a verdict
If you're obese but don't have diabetes, taking GLP-1 drugs like Ozempic for five years doesn't seem to raise your risk of joint problems like arthritis or needing joint surgery — so if joint issues show up in people with diabetes on these drugs, it might be because of their diabetes, not the drug itself.
Evidence from Studies
Supporting (0)
Community contributions welcome
Contradicting (1)
Community contributions welcome
The study found that obese adults without diabetes who took GLP-1 drugs for five years did not have higher rates of joint problems compared to those who didn’t, which supports the idea that the drug itself isn’t causing joint issues in this group.
Score Breakdown
No multi-axis breakdown available yet. The overall Pro / Against score above is the best signal.
- No clinical evidence is available; the score reflects mechanistic plausibility only.
What Would Prove This
Per GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this claim, ordered from strongest to weakest.
Systematic Review of GLP-1 Receptor Agonists and Joint Outcomes in Non-Diabetic Obese Adults
Systematic review and meta-analysis of prospective cohort studies and randomized controlled trials evaluating GLP-1 receptor agonist use over ≥3 years in obese (BMI ≥30) adults without type 2 diabetes, reporting incidence of hip/knee osteoarthritis, joint arthroplasty, and other musculoskeletal outcomes.
Five-Year Double-Blind Placebo-Controlled Trial of Semaglutide on Joint Health in Obese Non-Diabetic Adults
Double-blind, placebo-controlled RCT with 5-year follow-up, enrolling 3,000 obese adults without diabetes, randomized to semaglutide 2.4 mg weekly vs. placebo, with primary outcomes: incidence of radiographic knee/hip osteoarthritis and total joint arthroplasty.
Longitudinal Cohort Study of GLP-1 Use and Joint Outcomes in Non-Diabetic Obese Patients
Prospective cohort study tracking 10,000 obese adults without diabetes over five years, comparing those prescribed GLP-1 receptor agonists to matched controls, with adjudicated outcomes for osteoarthritis diagnoses and joint surgeries.
Case-Control Study of Joint Arthroplasty Risk in Obese Non-Diabetic Users of GLP-1 Receptor Agonists
Nested case-control study within a large healthcare database, matching 1,000 cases (obese non-diabetics undergoing total knee/hip arthroplasty) with 2,000 controls on age, sex, and BMI, assessing prior GLP-1 exposure.
Prevalence of Joint Symptoms in Obese Non-Diabetic Adults Using GLP-1 Receptor Agonists
National cross-sectional survey of 5,000 obese adults without diabetes, comparing self-reported joint pain, stiffness, and prior joint diagnoses between current GLP-1 users and non-users, adjusted for physical activity and weight history.